Drug intelligence / Profile preview

2-[2-ethanesulfonylamino-3-(1H-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamimidoyl-benzylamide)

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is an experimental small molecule classified as a dipeptide derivative. It has not been approved for use in the United States or other regions and does not have any known clinical indications or patents. The chemical formula is C26H33N7O5S, with an average molecular weight of approximately 555.65 Da. There is no available information on its mechanism of action, biological targets, or therapeutic applications[1][2].

Other names: 2-[2-ethanesulfonylamino-3-(1H-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamimidoyl-benzylamide)

Beyond the preview

Go deeper on 2-[2-ethanesulfonylamino-3-(1H-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamimidoyl-benzylamide).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-[2-ethanesulfonylamino-3-(1H-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamimidoyl-benzylamide).

Explore the full profile